BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022. [PMID: 35732831 DOI: 10.1038/s41375-022-01613-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 77] [Article Influence: 44.0] [Reference Citation Analysis]
Number Citing Articles
1 Brett VE, Lechevalier N, Trimoreau F, Dussiau C, Dimicoli-Salazar S, Coster L, Luquet I, Nadal N, Ribourtout B, Chapiro E, Lefebvre C, Tondeur S, Balducci E, Nguyen-Khac F, Borie C, Radford-Weiss I, Barin C, Eclache V, Mansier O, Bidet A; Groupe Francophone de Cytogénétique Hématologique (GFCH). The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significance. Genes Chromosomes Cancer 2023;62:139-51. [PMID: 36412977 DOI: 10.1002/gcc.23107] [Reference Citation Analysis]
2 Sun H, Yan H, Yan Z, Zhu Y, Yang G, Zhang S. Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT. Ann Hematol 2023;102:473-5. [PMID: 36434435 DOI: 10.1007/s00277-022-05047-8] [Reference Citation Analysis]
3 Vittayawacharin P, Kongtim P, Ciurea SO. Allogeneic stem cell transplantation for patients with myelodysplastic syndromes. Am J Hematol 2023;98:322-37. [PMID: 36251347 DOI: 10.1002/ajh.26763] [Reference Citation Analysis]
4 Huang J, Zhu Y, Li J, Yang G, Zhang S. The KMT2A rearrangement is an early event prior to KMT2A-PTD in AML patients with both molecular aberrations. Ann Hematol 2023;102:495-7. [PMID: 36525029 DOI: 10.1007/s00277-022-05074-5] [Reference Citation Analysis]
5 Ragusa D, Dijkhuis L, Pina C, Tosi S. Mechanisms associated with t(7;12) acute myeloid leukaemia: from genetics to potential treatment targets. Biosci Rep 2023;43:BSR20220489. [PMID: 36622782 DOI: 10.1042/BSR20220489] [Reference Citation Analysis]
6 Godley LA. Prioritization of patients for germline testing based on tumor profiling of hematopoietic malignancies. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1084736] [Reference Citation Analysis]
7 Sembill S, Ampatzidou M, Chaudhury S, Dworzak M, Kalwak K, Karow A, Kiani A, Krumbholz M, Luesink M, Naumann-Bartsch N, De Moerloose B, Osborn M, Schultz KR, Sedlacek P, Giona F, Zwaan CM, Shimada H, Versluijs B, Millot F, Hijiya N, Suttorp M, Metzler M. Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations. Leukemia 2023. [PMID: 36707619 DOI: 10.1038/s41375-023-01822-2] [Reference Citation Analysis]
8 Nguyen-Khac F, Bidet A, Troadec MB, Veronese L, Auger N, Daudignon A, Nadal N, Penther D, Michaux L, Lafage-Pochitaloff M, Lefebvre C. The 5th edition of the WHO classification of haematolymphoid tumors: comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH). Leukemia 2023. [PMID: 36707618 DOI: 10.1038/s41375-023-01821-3] [Reference Citation Analysis]
9 Chen EC, Johnston H, Patel AA. Targeted Therapy for MPNs: Going Beyond JAK Inhibitors. Curr Hematol Malig Rep 2023. [PMID: 36705855 DOI: 10.1007/s11899-023-00690-y] [Reference Citation Analysis]
10 O'Sullivan JM, Mead AJ, Psaila B. Single-cell methods in myeloproliferative neoplasms: old questions, new technologies. Blood 2023;141:380-90. [PMID: 36322938 DOI: 10.1182/blood.2021014668] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Hochhaus A, Ott G, Siebert R. WHO-Klassifikation 2022 chronischer myeloproliferativer Erkrankungen. Onkologie 2023. [DOI: 10.1007/s00761-023-01308-x] [Reference Citation Analysis]
12 Eckardt JN, Stasik S, Röllig C, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Hanoun M, Kaiser U, Kaufmann M, Rácil Z, Mayer J, Cerqueira T, Kroschinsky F, Berdel WE, Serve H, Müller-Tidow C, Platzbecker U, Baldus CD, Schetelig J, Siepmann T, Bornhäuser M, Middeke JM, Thiede C. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome. Blood Cancer J 2023;13:18. [PMID: 36693840 DOI: 10.1038/s41408-023-00790-1] [Reference Citation Analysis]
13 Greenberg PL. Myelodysplastic syndromes, thy name is heterogeneity. Br J Haematol 2023. [PMID: 36683593 DOI: 10.1111/bjh.18649] [Reference Citation Analysis]
14 Ernst T, Hochhaus A. Chronische myeloische Leukämie. Onkologie 2023. [DOI: 10.1007/s00761-022-01290-w] [Reference Citation Analysis]
15 Vráblová L, Divoký V, Kořalková P, Poláková KM, Kriegová E, Janská R, Grohmann J, Holzerová M, Papajík T, Faber E. Deep Molecular Response Achieved with Chemotherapy, Dasatinib and Interferon α in Patients with Lymphoid Blast Crisis of Chronic Myeloid Leukaemia. IJMS 2023;24:2050. [DOI: 10.3390/ijms24032050] [Reference Citation Analysis]
16 Elghetany MT, Cavé H, De Vito R, Patnaik MM, Solary E, Khoury JD. Juvenile myelomonocytic leukemia; moving forward. Leukemia 2023. [PMID: 36670234 DOI: 10.1038/s41375-023-01818-y] [Reference Citation Analysis]
17 Fizza Haider S, Sloss R, Jhanji S, Nicholson E, Creagh-Brown B. Management of adult patients with haematological malignancies in critical care. Anaesthesia 2023. [PMID: 36658786 DOI: 10.1111/anae.15955] [Reference Citation Analysis]
18 Liapis K, Papadopoulos V, Pontikoglou C, Vrachiolias G, Stavroulaki E, Kourakli A, Lazaris V, Galanopoulos AG, Papoutselis M, Papageorgiou SG, Diamantopoulos PT, Pappa V, Viniou NA, Τsokanas D, Vassilakopoulos TP, Hatzimichael E, Bouronikou E, Ximeri M, Megalakaki A, Zikos P, Panayiotidis P, Dimou M, Karakatsanis S, Papaioannou M, Papadakis S, Vardi A, Kontopidou F, Harchalakis N, Adamopoulos I, Symeonidis A, Papadaki HA, Kotsianidis I. Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries. Leukemia 2023. [PMID: 36646886 DOI: 10.1038/s41375-023-01819-x] [Reference Citation Analysis]
19 Zhao A, Zhao M, Qian W, Liang A, Li P, Liu H. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature. Front Immunol 2022;13:1063986. [PMID: 36713414 DOI: 10.3389/fimmu.2022.1063986] [Reference Citation Analysis]
20 Volpe VO, Garcia-Manero G, Komrokji RS. State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk 2023:S2152-2650(23)00002-2. [PMID: 36682988 DOI: 10.1016/j.clml.2023.01.001] [Reference Citation Analysis]
21 Vilov S, Heinig M. DeepSom: a CNN-based approach to somatic variant calling in WGS samples without a matched normal. Bioinformatics 2023;39. [PMID: 36637201 DOI: 10.1093/bioinformatics/btac828] [Reference Citation Analysis]
22 Pettirossi V, Venanzi A, Spanhol-Rosseto A, Schiavoni G, Santi A, Tasselli L, Naccari M, Pensato V, Pucciarini A, Martelli MP, Drexler H, Falini B, Tiacci E. The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor. Leukemia 2023. [PMID: 36635390 DOI: 10.1038/s41375-022-01788-7] [Reference Citation Analysis]
23 Madanat YF, Xie Z, Zeidan AM. Advances in myelodysplastic syndromes: promising novel agents and combination strategies. Expert Rev Hematol 2023;:1-13. [PMID: 36620919 DOI: 10.1080/17474086.2023.2166923] [Reference Citation Analysis]
24 Abel HJ, Oetjen KA, Miller CA, Ramakrishnan SM, Day RB, Helton NM, Fronick CC, Fulton RS, Heath SE, Tarnawsky SP, Srivatsan SN, Duncavage EJ, Schroeder MC, Payton JE, Spencer DH, Walter MJ, Westervelt P, DiPersio JF, Ley TJ, Link DC. Genomic landscape of TP53 -mutated myeloid malignancies. medRxiv 2023:2023. [PMID: 36711871 DOI: 10.1101/2023.01.10.23284322] [Reference Citation Analysis]
25 Tang Z, Wang W, Yang S, El Achi H, Fang H, Nahmod KA, Toruner GA, Xu J, Thakral B, Ayoub E, Issa GC, Yin CC, You MJ, Miranda RN, Khoury JD, Medeiros LJ, Tang G. 3q26.2/MECOM Rearrangements by Pericentric Inv(3): Diagnostic Challenges and Clinicopathologic Features. Cancers (Basel) 2023;15. [PMID: 36672407 DOI: 10.3390/cancers15020458] [Reference Citation Analysis]
26 Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Carrillo-Cruz E, Bilbao-Sieyro C, Prados de la Torre E, Martínez-Cuadrón D, Rodríguez-Veiga R, Boluda B, Gil C, Bernal T, Bergua JM, Algarra L, Tormo M, Martínez-Sánchez P, Soria E, Serrano J, Alonso-Domínguez JM, García-Boyero R, Amigo ML, Herrera-Puente P, Sayas MJ, Lavilla-Rubira E, Martínez-López J, Calasanz MJ, García-Sanz R, Pérez-Simón JA, Gómez-Casares MT, Sánchez-García J, Barragán E, Montesinos P, On Behalf Of Pethema Group. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry. Cancers (Basel) 2023;15. [PMID: 36672386 DOI: 10.3390/cancers15020438] [Reference Citation Analysis]
27 Buckstein R, Chodirker L, Yee KWL, Geddes M, Leitch HA, Christou G, Banerji V, Leber B, Khalaf D, St-Hilaire E, Finn N, Nevill T, Keating MM, Storring J, Parmentier A, Thambipillai A, Tang D, Westcott C, Cameron C, Spin P. The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leuk Lymphoma 2023;:1-11. [PMID: 36606533 DOI: 10.1080/10428194.2022.2156793] [Reference Citation Analysis]
28 Ortí G, Gras L, Zinger N, Finazzi MC, Sockel K, Robin M, Forcade E, Avenoso D, Kröger N, Finke J, Radujkovic A, Hunault-Berger M, Schroyens W, Zuckerman T, Bourhis JH, Chalandon Y, Bloor A, Schots R, de Wreede LC, Drozd-Sokolowska J, Raj K, Polverelli N, Czerw T, Hernández-Boluda JC, McLornan D, Yakoub-Agha I. Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol 2023. [PMID: 36606718 DOI: 10.1002/ajh.26833] [Reference Citation Analysis]
29 El Hussein S, Wang W. Plasmacytoid dendritic cells in the setting of myeloid neoplasms: Diagnostic guide to challenging pathologic presentations. Br J Haematol 2023. [PMID: 36606610 DOI: 10.1111/bjh.18632] [Reference Citation Analysis]
30 Orvain C, Rodríguez-Arbolí E, Othus M, Sandmaier BM, Deeg HJ, Appelbaum FR, Walter RB. Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia. Cancers (Basel) 2023;15. [PMID: 36672303 DOI: 10.3390/cancers15020352] [Reference Citation Analysis]
31 Falini B, Martelli MP. Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia. Am J Hematol 2023. [PMID: 36606297 DOI: 10.1002/ajh.26812] [Reference Citation Analysis]
32 Patnaik MM, Tefferi A. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. Am J Hematol 2023. [PMID: 36601682 DOI: 10.1002/ajh.26828] [Reference Citation Analysis]
33 Chia YC, Siti Asmaa MJ, Ramli M, Woon PY, Johan MF, Hassan R, Islam MA. Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology. Diagnostics (Basel) 2023;13. [PMID: 36611455 DOI: 10.3390/diagnostics13010163] [Reference Citation Analysis]
34 Schwaab J, Horny H, Hartmann K. Diagnostik und Therapie der systemischen Mastozytose. Onkologie 2023. [DOI: 10.1007/s00761-022-01269-7] [Reference Citation Analysis]
35 Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 2023. [PMID: 36594187 DOI: 10.1002/ajh.26822] [Reference Citation Analysis]
36 Mehta P, Telford N, Wragg C, Dillon R, Freeman S, Finnegan D, Hamblin A, Copland M, Knapper S. Recommendations for laboratory testing of UK patients with acute myeloid leukaemia. Br J Haematol 2023;200:150-9. [PMID: 36278472 DOI: 10.1111/bjh.18516] [Reference Citation Analysis]
37 Senapati J, Jabbour E, Kantarjian H, Short NJ. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia 2023;37:5-17. [PMID: 36309558 DOI: 10.1038/s41375-022-01736-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Mansoor N, Rafiq N, Maqsood S, Jabbar N. Preleukemic phase of chronic myelogenous leukemia-a diagnostic dilemma highlighting the significance of integrated reporting in pathology. Pediatric Hematology Oncology Journal 2023. [DOI: 10.1016/j.phoj.2023.01.007] [Reference Citation Analysis]
39 Müller J, Walter W, Haferlach C, Müller H, Fuhrmann I, Müller ML, Ruge H, Meggendorfer M, Kern W, Haferlach T, Stengel A. How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing. Leukemia 2023;37:217-21. [PMID: 36335263 DOI: 10.1038/s41375-022-01743-6] [Reference Citation Analysis]
40 Zeidan AM, Bewersdorf JP, Hasle V, Shallis RM, Thompson E, de Menezes DL, Rose S, Boss I, Halene S, Haferlach T, Fox B. Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy. Leukemia 2023;37:240-3. [PMID: 36437356 DOI: 10.1038/s41375-022-01766-z] [Reference Citation Analysis]
41 Wang W, Khoury JD. Where diagnosis for myelodysplastic neoplasms (MDS) stands today and where it will go: The role of flow cytometry in evaluation of MDS. Cytometry B Clin Cytom 2023;104:12-4. [PMID: 36573832 DOI: 10.1002/cyto.b.22110] [Reference Citation Analysis]
42 Li N, Fan L, Xu H, Zhang X, Bai Z, Li M, Xiong S, Jiang L, Yang J, Chen S, Qiao Y, Chen B. An AI-aided diagnostic framework for hematologic neoplasms based on morphological features and medical expertise. Laboratory Investigation 2023. [DOI: 10.1016/j.labinv.2022.100055] [Reference Citation Analysis]
43 Tarantini F, Cumbo C, Zagaria A, Anelli L, Parciante E, Redavid I, Coccaro N, Tota G, Conserva MR, Minervini CF, Minervini A, Attolico I, Rossi AR, Specchia G, Musto P, Albano F. Clonal hematopoiesis onset in chronic myeloid leukemia: a novel player in a dangerous circuit. Leukemia Research 2023. [DOI: 10.1016/j.leukres.2023.107023] [Reference Citation Analysis]
44 Alsaati AM, Alasiri MM, Alansari BA, Mulla WY, Al-Marzouki AF, Daous YM, Radhwi O. Unusual Presentation of Leukemic-Phase Mantle Cell Lymphoma: A Case Report. Cureus 2023;15:e33239. [PMID: 36601362 DOI: 10.7759/cureus.33239] [Reference Citation Analysis]
45 Prakash S, Arber DA, Bueso-Ramos C, Hasserjian RP, Orazi A. Advances in myelodysplastic/myeloproliferative neoplasms. Virchows Arch 2023;482:69-83. [PMID: 36469102 DOI: 10.1007/s00428-022-03465-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Patel AA, Odenike O. Accelerated Phase of MPN: What It Is and What to Do About It. Clinical Lymphoma Myeloma and Leukemia 2023. [DOI: 10.1016/j.clml.2023.01.011] [Reference Citation Analysis]
47 Weinberg OK, Porwit A, Orazi A, Hasserjian RP, Foucar K, Duncavage EJ, Arber DA. The International Consensus Classification of acute myeloid leukemia. Virchows Arch 2023;482:27-37. [PMID: 36264379 DOI: 10.1007/s00428-022-03430-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Thiele J, Kvasnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM, Barbui T, Arber DA, Tefferi A. The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol 2023;98:166-79. [PMID: 36200127 DOI: 10.1002/ajh.26751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
49 Kern W, van de Loosdrecht A. Flow cytometry in the diagnosis of myelodysplastic syndromes. Cytometry B Clin Cytom 2023;104:10-1. [PMID: 36409089 DOI: 10.1002/cyto.b.22103] [Reference Citation Analysis]
50 Calvo X. Should we give oligomonocytic chronic myelomonocytic leukemia a higher prominence in the next WHO Classification of Haematolymphoid Tumors? Leukemia 2023;37:250-1. [PMID: 36385279 DOI: 10.1038/s41375-022-01760-5] [Reference Citation Analysis]
51 Khalatbari H, Shulkin BL, Parisi MT. Emerging Trends in Radionuclide Imaging of Infection and Inflammation in Pediatrics: Focus on FDG PET/CT and Immune Reactivity. Semin Nucl Med 2023;53:18-36. [PMID: 36307254 DOI: 10.1053/j.semnuclmed.2022.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Valent P, Klion AD, Roufosse F, Simon D, Metzgeroth G, Leiferman KM, Schwaab J, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Hoermann G, Haferlach T, Moriggl R, George TI, Akin C, Bochner BS, Gotlib J, Reiter A, Horny HP, Arock M, Simon HU, Gleich GJ. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy 2023;78:47-59. [PMID: 36207764 DOI: 10.1111/all.15544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Oertling E, Fuda F, Koduru P, Chen M, Weinberg O, Juntilla M, Jaso J, Vusirikala M, Chung S, Geethakumari PR, Madanat YF, Collins R, Gagan J, Chen W. Distinct mutational and clinicopathologic profiles characterize acute myeloid leukemia with cup-like nuclei. Leuk Res 2023;124:106995. [PMID: 36459761 DOI: 10.1016/j.leukres.2022.106995] [Reference Citation Analysis]
54 Polprasert C, Niparuck P, Rattanathammethee T, Kobbuaklee S, Lanamtieng T, Rojnuckarin P. Comparison of Molecular International Prognostic Scoring System (M-IPSS) and Revised International Prognostic Scoring System (R-IPSS) in Thai patients with myelodysplastic neoplasms. Hematology 2022;27:1294-1297. [DOI: 10.1080/16078454.2022.2156682] [Reference Citation Analysis]
55 Zhang L, Campion V, Dickson M, Tang C. Acute myeloid leukaemia with NPM1 mutation: no longer having an absolute blast (count). Pathology 2022:S0031-3025(22)00687-0. [PMID: 36707319 DOI: 10.1016/j.pathol.2022.10.009] [Reference Citation Analysis]
56 Damiani D, Tiribelli M. Present and Future Role of Immune Targets in Acute Myeloid Leukemia. Cancers (Basel) 2022;15. [PMID: 36612249 DOI: 10.3390/cancers15010253] [Reference Citation Analysis]
57 Gurnari C, Xie Z, Zeidan AM. How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms. Clin Hematol Int 2022. [DOI: 10.1007/s44228-022-00024-4] [Reference Citation Analysis]
58 Voelker D, Bednarski JJ, Nieman E, Carter MC, Polk B. Hematopoietic KIT D816Y mutation presenting as in utero aggressive systemic mastocytosis with response to midostaurin. J Allergy Clin Immunol Pract 2022:S2213-2198(22)01329-0. [PMID: 36581075 DOI: 10.1016/j.jaip.2022.12.016] [Reference Citation Analysis]
59 Kuehn C, Schmidts I, Haferlach T. Diagnostik von leukämischen Erkrankungen. TD 2022;20:282-285. [DOI: 10.47184/td.2022.04.05] [Reference Citation Analysis]
60 Giudice V, Serio B, Ferrara I, Manzo P, Gorrese M, Pepe R, Bertolini A, D'Alto F, Verdesca F, Langella M, Filippelli A, Selleri C. Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience. Front Pharmacol 2022;13:1052060. [PMID: 36618908 DOI: 10.3389/fphar.2022.1052060] [Reference Citation Analysis]
61 Velletrani G, Francavilla B, Rosati V, Padial B, Anemona L, Girolamo SD. Adult onset Xanthogranuloma presenting as a solitary laryngeal localization: case report and review of literature. Arch Clin Cases 2022;9:145-9. [PMID: 36628161 DOI: 10.22551/2022.37.0904.10221] [Reference Citation Analysis]
62 Zhang Y, Nguyen L, Lu CM, Wang E, Lauw MIS, Ball S, Dong N, Moscinski L, Chan O, Yun S, Sallman D, Sokol L, Shah B, Knepper T, Lancet J, Komrokji R, Padron E, Kuykendall A, Zhang L. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion. Clin Lymphoma Myeloma Leuk 2022:S2152-2650(22)01773-6. [PMID: 36624015 DOI: 10.1016/j.clml.2022.12.008] [Reference Citation Analysis]
63 Kanagal-shamanna R. Never too old to blame it on your (inherited) genes. Blood 2022;140:2521-2523. [DOI: 10.1182/blood.2022017880] [Reference Citation Analysis]
64 Kao HW, Kuo MC, Huang YJ, Chang H, Hu SF, Huang CF, Hung YS, Lin TL, Ou CW, Lien MY, Wu JH, Chen CC, Shih LY. Measurable Residual Disease Monitoring by Locked Nucleic Acid Quantitative Real-Time PCR Assay for IDH1/2 Mutation in Adult AML. Cancers (Basel) 2022;14. [PMID: 36551690 DOI: 10.3390/cancers14246205] [Reference Citation Analysis]
65 Green SD, Zeidner JF. TP53 or Not TP53: That Is the Question. Clin Cancer Res 2022;28:5235-7. [PMID: 36197410 DOI: 10.1158/1078-0432.CCR-22-2664] [Reference Citation Analysis]
66 López C, Burkhardt B, Chan JKC, Leoncini L, Mbulaiteye SM, Ogwang MD, Orem J, Rochford R, Roschewski M, Siebert R. Burkitt lymphoma. Nat Rev Dis Primers 2022;8:78. [PMID: 36522349 DOI: 10.1038/s41572-022-00404-3] [Reference Citation Analysis]
67 Coltoff A. Leukocytosis and MPNs: Where do we stand? Leukemia & Lymphoma 2022. [DOI: 10.1080/10428194.2022.2156794] [Reference Citation Analysis]
68 Zheng J, Qiu D, Jiang X, Zhao Y, Zhao H, Wu X, Chen J, Lai J, Zhang W, Li X, Li Y, Wu X, Jin Z. Increased PD-1(+)Foxp3(+) γδ T cells associate with poor overall survival for patients with acute myeloid leukemia. Front Oncol 2022;12:1007565. [PMID: 36591503 DOI: 10.3389/fonc.2022.1007565] [Reference Citation Analysis]
69 Brunner AM, Leitch HA, van de Loosdrecht AA, Bonadies N. Management of patients with lower-risk myelodysplastic syndromes. Blood Cancer J 2022;12:166. [PMID: 36517487 DOI: 10.1038/s41408-022-00765-8] [Reference Citation Analysis]
70 Duarte NL, Bueno APS, Sanches BS, Ramos GA, Santos JMBD, Silva HFHE, de Oliveira Pondé J, de Sá JG, Rossi PM, Horn PRCB, das Neves Sztajnbok DC, de Paula Motta Rubini N, Milito CB, de Abreu TF, Land MGP. Incidence and Clinical Description of Lymphomas in Children and Adolescents with Vertical Transmission of HIV in Rio de Janeiro, Brazil, in Pre- and Post-Combined Antiretroviral Therapy Eras: A Multicentric Hospital-Based Survival Analysis Study. Cancers (Basel) 2022;14. [PMID: 36551614 DOI: 10.3390/cancers14246129] [Reference Citation Analysis]
71 Karakaslar EO, Severens J, Sánchez-lópez E, van Veelen PA, Zlei M, van Dongen JJ, Otte AM, Halkes CJ, van Balen P, Veelken H, Reinders MJ, Griffioen M, van den Akker EB. Single cell guided deconvolution of bulk transcriptomics recapitulates differentiation stages of acute myeloid leukemia and predicts drug response.. [DOI: 10.1101/2022.12.09.519738] [Reference Citation Analysis]
72 Cazzola M. Risk stratifying MDS in the time of precision medicine. Hematology Am Soc Hematol Educ Program 2022;2022:375-81. [PMID: 36485160 DOI: 10.1182/hematology.2022000349] [Reference Citation Analysis]
73 Vannucchi AM, Guglielmelli P. Molecular prognostication in Ph-negative MPNs in 2022. Hematology Am Soc Hematol Educ Program 2022;2022:225-34. [PMID: 36485130 DOI: 10.1182/hematology.2022000339] [Reference Citation Analysis]
74 Gotlib J. Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms. Hematology Am Soc Hematol Educ Program 2022;2022:34-46. [PMID: 36485158 DOI: 10.1182/hematology.2022000368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Roberts I. Leukemogenesis in infants and young children with trisomy 21. Hematology Am Soc Hematol Educ Program 2022;2022:1-8. [PMID: 36485097 DOI: 10.1182/hematology.2022000395] [Reference Citation Analysis]
76 Aubrey BJ, Brunner A. Evidence-Based Minireview: Clinical utilization of panel-based molecular testing for patients with AML. Hematology Am Soc Hematol Educ Program 2022;2022:30-3. [PMID: 36485121 DOI: 10.1182/hematology.2022000417] [Reference Citation Analysis]
77 Matthews A, Pratz KW. Optimizing outcomes in secondary AML. Hematology Am Soc Hematol Educ Program 2022;2022:23-9. [PMID: 36485116 DOI: 10.1182/hematology.2022000324] [Reference Citation Analysis]
78 Sedeta E, Pokhrel A, Nair K, Gotlieb V. Intraoral myeloid sarcoma presenting as toothache and gingival mass. BMJ Case Rep 2022;15. [PMID: 36593620 DOI: 10.1136/bcr-2022-251452] [Reference Citation Analysis]
79 Aster JC. What is in a Name? Consequences of the Classification Schism in Hematopathology. J Clin Oncol 2022;:JCO2202680. [PMID: 36480786 DOI: 10.1200/JCO.22.02680] [Reference Citation Analysis]
80 Im S, Kim JA, Park G, Cho U. Systemic Lymphadenopathic Mastocytosis with Eosinophilia. Diagnostics (Basel) 2022;12. [PMID: 36553063 DOI: 10.3390/diagnostics12123057] [Reference Citation Analysis]
81 Huber S, Haferlach T, Meggendorfer M, Hutter S, Hoermann G, Summerer I, Fuhrmann I, Baer C, Kern W, Haferlach C. Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts. Leukemia 2022. [DOI: 10.1038/s41375-022-01783-y] [Reference Citation Analysis]
82 Qin Y, Zhang H, Feng L, Wei H, Wu Y, Jiang C, Xu Z, Zhu H, Liu T. Combining metaphase cytogenetics with single nucleotide polymorphism arrays can improve the diagnostic yield and identify prognosis more precisely in myelodysplastic syndromes. Ann Med 2022;54:2627-36. [PMID: 36148999 DOI: 10.1080/07853890.2022.2125173] [Reference Citation Analysis]
83 Marques FK, Sabino ADP. Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment. Biomedicine & Pharmacotherapy 2022;156:113905. [DOI: 10.1016/j.biopha.2022.113905] [Reference Citation Analysis]
84 Su Z, Liu X, Hu W, Yang J, Yin X, Hou F, Wang Y, Zhang J. Myeloid neoplasm with ETV6::ACSl6 fusion: landscape of molecular and clinical features. Hematology 2022;27:1010-8. [PMID: 36069745 DOI: 10.1080/16078454.2022.2117206] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Lee WH, Lin CC, Tsai CH, Tseng MH, Kuo YY, Liu MC, Tang JL, Sun HI, Chuang YK, Chou WC, Hou HA, Tien HF. Effect of mutation allele frequency on the risk stratification of myelodysplastic syndrome patients. Am J Hematol 2022;97:1589-98. [PMID: 36109871 DOI: 10.1002/ajh.26734] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
86 Podvin B, Roynard P, Boudry A, Guermouche H, Daudignon A, Terriou L, Bouabdelli W, Salameh M, Grardel N, Duployez N, Roche-lestienne C. Whole-genome optical mapping to elucidate myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions. Leukemia Research 2022;123:106972. [DOI: 10.1016/j.leukres.2022.106972] [Reference Citation Analysis]
87 Cuppen E, Elemento O, Rosenquist R, Nikic S, IJzerman M, Zaleski ID, Frederix G, Levin LÅ, Mullighan CG, Buettner R, Pugh TJ, Grimmond S, Caldas C, Andre F, Custers I, Campo E, van Snellenberg H, Schuh A, Nakagawa H, von Kalle C, Haferlach T, Fröhling S, Jobanputra V. Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care. JCO Precis Oncol 2022;6:e2200245. [PMID: 36480778 DOI: 10.1200/PO.22.00245] [Reference Citation Analysis]
88 Modemann F, Ghandili S, Zhurba I, Langer F, Bokemeyer C, Fiedler W. Die akute Promyelozytenleukämie - ein hämatologischer Notfall. InFo Hämatol Onkol 2022;25:10-15. [DOI: 10.1007/s15004-022-9772-1] [Reference Citation Analysis]
89 Bouanani N, Bouyaqine H, Coulibaly K, Benslima N, Youssefi H. Acute Myeloid Leukemia Revealed by a Palatal Necrosis: A Rare Case Report. Cureus 2022;14:e32350. [PMID: 36628024 DOI: 10.7759/cureus.32350] [Reference Citation Analysis]
90 Wang Z, Guo J, Liu J. A Patient with Acute Erythroid Leukaemia with Granular Leukaemic Cells Mimicking Megakaryoblast. Indian J Hematol Blood Transfus 2022. [DOI: 10.1007/s12288-022-01616-z] [Reference Citation Analysis]
91 Zhang S, Croppi G, Hu H, Li Y, Zhu C, Wu F, Zhang F, Li Z. Bacillamide F, Extracted from Marine Bacillus atrophaeus C89, Preliminary Effects on Leukemia Cell Lines. Biology (Basel) 2022;11. [PMID: 36552221 DOI: 10.3390/biology11121712] [Reference Citation Analysis]
92 Ortuzar A, Fox ML, Vera JA, Lorenzo Vizcaya Á, Marín Sánchez A, Llopis Calatayud I, Carbonell S, Álvarez-Larrán A, Mata Serna R, Marco Buades JE, Quiroz Cervantes K, Martínez Hellín Á, Blum Domínguez A, Caballero Navarro G, Cáceres Sansaloni A, Guerrero Fernández L, Muñoz Linares C, Gasior Kabat M, Pérez López R, Fernández Rodríguez Á, Martínez Bilbao C, Cobo Rodríguez MT, Díaz Á, Durán MA, Santaliestra Tomas M, García-Gutierrez V, Magro Mazo E, Hernández-Boluda JC, Segura A, Raya JM, Navas Elorza B, Osorio S. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain. Ann Hematol 2023;102:447-56. [PMID: 36422672 DOI: 10.1007/s00277-022-05044-x] [Reference Citation Analysis]
93 Arai H, Minami Y, Chi S, Utsu Y, Masuda S, Aotsuka N. Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. Biomedicines 2022;10. [PMID: 36551764 DOI: 10.3390/biomedicines10123008] [Reference Citation Analysis]
94 El Hussein S, Loghavi S. The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms. Cancers (Basel) 2022;14. [PMID: 36428782 DOI: 10.3390/cancers14225690] [Reference Citation Analysis]
95 Drozd-sokolowska J, Gras L, Zinger N, Zahrani MA, Passweg J, Byrne J, Ho A, Huang X, Kröger N, Mayer J, Russo D, De Becker A, Tbakhi A, Stamatoullas A, Valerius T, Hayden P, Mclornan DP, Onida F, Scheid C, Robin M, Yakoub-agha I. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant 2022. [DOI: 10.1038/s41409-022-01870-9] [Reference Citation Analysis]
96 Shen J, Liu J. Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1034668] [Reference Citation Analysis]
97 Li H, Hu F, Gale RP, Sekeres MA, Liang Y. Myelodysplastic syndromes. Nat Rev Dis Primers 2022;8:74. [DOI: 10.1038/s41572-022-00402-5] [Reference Citation Analysis]
98 Lierman E, Smits S, Debackere K, André M, Michaux L, Vandenberghe P. t(9;12)(q22;p13) ETV6::SYK : A new recurrent cytogenetic aberration and tyrosine kinase gene fusion in myeloid or lymphoid neoplasms associated with eosinophilia. Br J Haematol 2022. [DOI: 10.1111/bjh.18569] [Reference Citation Analysis]
99 Zhao D, Eladl E, Zarif M, Capo‐chichi J, Schuh A, Atenafu E, Minden M, Chang H. Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC ‐defining criteria, TP53 allelic state, or TP53 variant allele frequency. Cancer Medicine 2022. [DOI: 10.1002/cam4.5421] [Reference Citation Analysis]
100 Shi Y, Chen C, Huang Y, Xu Y, Xu D, Shen H, Ye X, Jin J, Tong H, Yu Y, Tang X, Li A, Cui D, Xie W. Global disease burden and trends of leukemia attributable to occupational risk from 1990 to 2019: An observational trend study. Front Public Health 2022;10:1015861. [PMID: 36452945 DOI: 10.3389/fpubh.2022.1015861] [Reference Citation Analysis]
101 Acha P, Mallo M, Solé F. Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment. Cancers (Basel) 2022;14. [PMID: 36428627 DOI: 10.3390/cancers14225531] [Reference Citation Analysis]
102 Dieckmann K, Isbarn H, Grobelny F, Dumlupinar C, Utschig J, Wülfing C, Pichlmeier U, Belge G. Testicular Neoplasms: Primary Tumour Size Is Closely Interrelated with Histology, Clinical Staging, and Tumour Marker Expression Rates—A Comprehensive Statistical Analysis. Cancers 2022;14:5447. [DOI: 10.3390/cancers14215447] [Reference Citation Analysis]
103 Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, Dezern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia 2022. [DOI: 10.1038/s41375-022-01754-3] [Reference Citation Analysis]
104 Bhuyan B, Padhi S, Kumar Das P, Panigrahi C. Chronic Myeloid Leukemia: Biology, Diagnosis, and Management. Leukemia - From Biology to Diagnosis and Treatment [Working Title] 2022. [DOI: 10.5772/intechopen.108334] [Reference Citation Analysis]
105 Li T, Zhang G, Zhang X, Lin H, Liu Q. The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1015792] [Reference Citation Analysis]
106 Weinberg OK, Dennis J, Zia H, Chen P, Chu A, Koduru P, Luu HS, Fuda F, Chen W. Adult mixed phenotype acute leukemia ( MPAL ): B/myeloid MPAL isoMPO is distinct from other MPAL subtypes. Int J Lab Hematology 2022. [DOI: 10.1111/ijlh.13988] [Reference Citation Analysis]
107 Kaaren K. Reichard, Ayalew Tefferi, Maymona Abdelmagid, Attilio Orazi, Christina Alexandres, Joanna Haack, Patricia T. Greipp. Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases. Blood Cancer J 2022;12:147. [PMID: 36323674 DOI: 10.1038/s41408-022-00746-x] [Reference Citation Analysis]
108 Götze KS, Lengerke C. [Importance of clonal hematopoiesis for hematologic neoplasms]. Inn Med (Heidelb) 2022;63:1107-14. [PMID: 36125513 DOI: 10.1007/s00108-022-01401-0] [Reference Citation Analysis]
109 Xie Z, Chen EC, Stahl M, Zeidan AM. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.101033] [Reference Citation Analysis]
110 O’sullivan J, Psaila B. Lords of the Iron Rings: Coordinated Missplicing of TMEM14C and ABCB7 Drives Ring Sideroblast Formation in SF3B1-Mutant MDS. The Hematologist 2022;19. [DOI: 10.1182/hem.v19.6.202266] [Reference Citation Analysis]
111 Schwaab J, Lübke J, Reiter A, Metzgeroth G. Das idiopathische hypereosinophile Syndrom - Diagnostik und Therapie. Allergo J 2022;31:44-50. [DOI: 10.1007/s15007-022-5600-z] [Reference Citation Analysis]
112 Ambinder AJ, Dezern AE. Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1033534] [Reference Citation Analysis]
113 Elbaz Younes I, Sokol L, Zhang L. Rosai–Dorfman Disease between Proliferation and Neoplasia. Cancers 2022;14:5271. [DOI: 10.3390/cancers14215271] [Reference Citation Analysis]
114 Rungjirajittranon T, Siriwannangkul T, Kungwankiattichai S, Leelakanok N, Rotchanapanya W, Vittayawacharin P, Mekrakseree B, Kulchutisin K, Owattanapanich W. Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis. Cancers 2022;14:5239. [DOI: 10.3390/cancers14215239] [Reference Citation Analysis]
115 Le Pannérer MM, Diesch J, Casquero R, Maher M, Garcia O, Haferlach T, Zuber J, Kündgen A, Götze KS, Buschbeck M. Different Gene Sets Are Associated With Azacitidine Response In Vitro Versus in Myelodysplastic Syndrome Patients. Hemasphere 2022;6:e792. [PMID: 36310757 DOI: 10.1097/HS9.0000000000000792] [Reference Citation Analysis]
116 Heidel FH, Crodel CC, Kreipe HH. Primäre Myelofibrose. Onkologie 2022. [DOI: 10.1007/s00761-022-01253-1] [Reference Citation Analysis]
117 Niemeyer CM, Rudelius M, Shimamura A, Flotho C, Hasle H, Stieglitz E, Strahm B, Godley LA, Weinberg OK, Orazi A, Calvo KR. Classification of rare pediatric myeloid neoplasia-Quo vadis? Leukemia 2022. [PMID: 36271151 DOI: 10.1038/s41375-022-01731-w] [Reference Citation Analysis]
118 Paes J, Silva GAV, Tarragô AM, Mourão LPDS. The Contribution of JAK2 46/1 Haplotype in the Predisposition to Myeloproliferative Neoplasms. IJMS 2022;23:12582. [DOI: 10.3390/ijms232012582] [Reference Citation Analysis]
119 Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia 2022. [PMID: 36266326 DOI: 10.1038/s41375-022-01724-9] [Reference Citation Analysis]
120 Huber S, Haferlach T, Meggendorfer M, Hutter S, Hoermann G, Baer C, Kern W, Haferlach C. SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis. Leukemia 2022. [PMID: 36261576 DOI: 10.1038/s41375-022-01728-5] [Reference Citation Analysis]
121 Shibusawa M, Tanimoto T. Acute Myeloid Leukemia with Myelodysplasia Related Changes. Leukemia 2022. [DOI: 10.36255/exon-publications-leukemia-aml-mrca] [Reference Citation Analysis]
122 Kurz KS, Ott G. Die 5. Ausgabe der WHO-Klassifikation lymphatischer Neoplasien – ein Überblick. Pathologie 2022. [DOI: 10.1007/s00292-022-01132-x] [Reference Citation Analysis]
123 Rosli AA, Azlan A, Rajasegaran Y, Mot YY, Heidenreich O, Yusoff NM, Moses EJ. Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications. Clin Exp Med 2022. [PMID: 36229751 DOI: 10.1007/s10238-022-00913-1] [Reference Citation Analysis]
124 Gupta A, Gupta N. Clinical application of molecular genetics in acute myeloid leukemia. IJMIO 2022;0:1-6. [DOI: 10.25259/ijmio_22_2022] [Reference Citation Analysis]
125 Zhang Y, Wu J, Qin T, Xu Z, Qu S, Pan L, Li B, Wang H, Zhang P, Yan X, Gong J, Gao Q, Gale RP, Xiao Z. Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms. Leukemia 2022. [PMID: 36224330 DOI: 10.1038/s41375-022-01718-7] [Reference Citation Analysis]
126 Cooperrider JH, Shukla N, Nawas MT, Patel AA. The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia. JCO Oncology Practice 2022. [DOI: 10.1200/op.22.00342] [Reference Citation Analysis]
127 Cassanello G, Pasquale R, Barcellini W, Fattizzo B. Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes. Cancers (Basel) 2022;14:4941. [PMID: 36230864 DOI: 10.3390/cancers14194941] [Reference Citation Analysis]
128 Raskovalova T, Scheffen L, Jacob MC, Chevalier S, Tondeur S, Bulabois B, Meunier M, Szymanski G, Lefebvre C, Planta C, Dumestre-Perard C, Gonnet N, Garban F, Merle R, Park S, Labarère J. Flow cytometry lyophilised-reagent tube for quantifying peripheral blood neutrophil myeloperoxidase expression in myelodysplastic syndromes (MPO-MDS-Develop): protocol for a diagnostic accuracy study. BMJ Open 2022;12:e065850. [PMID: 36207039 DOI: 10.1136/bmjopen-2022-065850] [Reference Citation Analysis]
129 Abeykoon JP, Rech KL, Young JR, Ravindran A, Ruan GJ, Dasari S, Morlote DM, King RL, Rummage C, Zanwar S, Acosta-Medina AM, Tobin WO, Shah MV, Bennani NN, Vassallo R, Ryu JH, Koster MJ, Davidge-Pitts CJ, Witzig TE, Goyal G, Go RS; Mayo Clinic–University of Alabama at Birmingham Histiocytosis Working Group. Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status. JAMA Oncol 2022. [PMID: 36201194 DOI: 10.1001/jamaoncol.2022.4432] [Reference Citation Analysis]
130 Jia Y, Lin D, Wang Z, Li C, Wang H, Wang J, Mi Y. Diagnostic challenge in mixed phenotype acute leukemia with T/megakaryocyte or T/myeloid lineages accompanied by t(3;3). Diagn Pathol 2022;17:74. [PMID: 36199105 DOI: 10.1186/s13000-022-01257-w] [Reference Citation Analysis]
131 Walter W, Pohlkamp C, Meggendorfer M, Nadarajah N, Kern W, Haferlach C, Haferlach T. Artificial intelligence in hematological diagnostics: Game changer or gadget? Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.101019] [Reference Citation Analysis]
132 Hochman MJ, Smith BD, Karantanos T, Braunstein EM, Gojo I, Jain T, Streiff MB, Moliterno AR, DeZern AE. Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency. Int J Hematol 2022. [PMID: 36181657 DOI: 10.1007/s12185-022-03463-0] [Reference Citation Analysis]
133 López C, Mozas P, López-guillermo A, Beà S. Molecular Pathogenesis of Follicular Lymphoma: From Genetics to Clinical Practice. Hemato 2022;3:595-614. [DOI: 10.3390/hemato3040041] [Reference Citation Analysis]
134 Bhavsar S, Jain S, Yatsenko S, Surti U, Swerdlow S, Aggarwal N. Immunophenotypic and Molecular Cytogenetic Associations of CD19 Expression in Acute Myeloid Leukemias, including in the t(8;21) negative setting.. [DOI: 10.21203/rs.3.rs-2023169/v1] [Reference Citation Analysis]
135 Hennawi M, Pakasticali N, Tashkandi H, Hussaini M. Genomic Landscape of Mixed-Phenotype Acute Leukemia. IJMS 2022;23:11259. [DOI: 10.3390/ijms231911259] [Reference Citation Analysis]
136 Haferlach C, Heuser M. Diagnostik bei unklaren Zytopenien – wie und wann suchen wir nach klonaler Hämatopoese? Innere Medizin 2022. [DOI: 10.1007/s00108-022-01402-z] [Reference Citation Analysis]
137 Iurlo A, Cattaneo D. Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management? Blood Rev 2022;:101014. [PMID: 36153195 DOI: 10.1016/j.blre.2022.101014] [Reference Citation Analysis]
138 Toya T, Harada H, Harada Y, Doki N. Adult-onset hereditary myeloid malignancy and allogeneic stem cell transplantation. Front Oncol 2022;12:997530. [DOI: 10.3389/fonc.2022.997530] [Reference Citation Analysis]
139 Llop M, Sargas C, Barragán E. The role of next-generation sequencing in acute myeloid leukemia. Current Opinion in Oncology 2022;Publish Ahead of Print. [DOI: 10.1097/cco.0000000000000899] [Reference Citation Analysis]
140 Testa U, Castelli G, Pelosi E. Genome-Based Medicine for Acute Myeloid Leukemia: Study and Targeting of Molecular Alterations and Use of Minimal Residual Disease as a Biomarker. Hemato 2022;3:543-568. [DOI: 10.3390/hemato3030038] [Reference Citation Analysis]
141 Sekeres MA, Taylor J. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. JAMA 2022;328:872-80. [PMID: 36066514 DOI: 10.1001/jama.2022.14578] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
142 Radia DH, Moonim MT. Update on diagnostic approaches and therapeutic strategies in systemic mastocytosis. Best Practice & Research Clinical Haematology 2022. [DOI: 10.1016/j.beha.2022.101380] [Reference Citation Analysis]
143 Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20:1033-62. [PMID: 36075392 DOI: 10.6004/jnccn.2022.0046] [Reference Citation Analysis]
144 Macon WR. Competing hematolymphoid classification schemes on deck. J Hematopathol 2022;15:115-115. [DOI: 10.1007/s12308-022-00511-w] [Reference Citation Analysis]
145 Rausch C, Hiddemann W, von Bergwelt-baildon M, Spiekermann K, Herold T. Akute Myeloische Leukämien – Update 2022. Dtsch Med Wochenschr 2022;147:1108-14. [DOI: 10.1055/a-1758-2452] [Reference Citation Analysis]
146 Gale RP. Radiation and leukaemia: Which leukaemias and what doses? Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.101017] [Reference Citation Analysis]
147 Steensma DP, Bejar R, Jaiswal S, Sekeres MA, Hasserjian RP, Ebert BL. In Response to Lymphohematopoietic Clones. The Hematologist 2022;19. [DOI: 10.1182/hem.v19.5.2022517] [Reference Citation Analysis]
148 Nicholson AG, Scagliotti G, Tsao MS, Yatabe Y, Travis WD. 2021 WHO Classification of Lung Cancer: A Globally Applicable and Molecular Biomarker-Relevant Classification. J Thorac Oncol 2022;17:e80-3. [PMID: 36031295 DOI: 10.1016/j.jtho.2022.07.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Rodriguez-sevilla JJ, Calvo X, Arenillas L. Causes and Pathophysiology of Acquired Sideroblastic Anemia. Genes 2022;13:1562. [DOI: 10.3390/genes13091562] [Reference Citation Analysis]
150 Stubbins RJ, Francis A, Kuchenbauer F, Sanford D. Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology. Current Oncology 2022;29:6245-6259. [DOI: 10.3390/curroncol29090491] [Reference Citation Analysis]
151 Xu ML, Katz SG. Response to Letter to the Editor: IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias but does not Discriminate Between Monoblasts and Plasmacytoid Dendritic Cells. Am J Surg Pathol 2022. [PMID: 36040049 DOI: 10.1097/PAS.0000000000001961] [Reference Citation Analysis]
152 Awada H, Mustafa Ali MK, Thapa B, Awada H, Seymour L, Liu L, Gurnari C, Kishtagari A, Wang E, Baer MR. A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges. Cancers 2022;14:4166. [DOI: 10.3390/cancers14174166] [Reference Citation Analysis]
153 Swerdlow SH, Campo E, Arber DA, Cazzola M, Cook JR, Döhner H, Dreyling M, Hasserjian RP, Jaffe ES, Orazi A, Quintanilla-Martinez L, Scott DW, Tefferi A, Winter JN, Zelenetz AD. Response to "The WHO classification of haematolymphoid tumours" (Editorial). Leukemia 2022. [PMID: 36030304 DOI: 10.1038/s41375-022-01689-9] [Reference Citation Analysis]
154 Hoermann G. Clonal hematopoiesis of indeterminate potential: clinical relevance of an incidental finding in liquid profiling. LaboratoriumsMedizin 2022;46:301-310. [DOI: 10.1515/labmed-2022-0050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Renosi F, Callanan M, Lefebvre C. Genetics and Epigenetics in Neoplasms with Plasmacytoid Dendritic Cells. Cancers 2022;14:4132. [DOI: 10.3390/cancers14174132] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
156 Ranieri R, Pianigiani G, Sciabolacci S, Perriello VM, Marra A, Cardinali V, Pierangeli S, Milano F, Gionfriddo I, Brunetti L, Martelli MP, Falini B. Current status and future perspectives in targeted therapy of NPM1-mutated AML. Leukemia 2022. [PMID: 36008542 DOI: 10.1038/s41375-022-01666-2] [Reference Citation Analysis]
157 Cruz-chávez DA, López-pérez BJ, Solórzano-gómez E, Venta-sobero JA, Flores-villegas LV, Toledo-lozano CG, Castro-loza GV, Sandoval-pacheco R, Torres-vallejo A, Marmol-realpe KSF, Flores-jurado YE, Hernández-soriano CL, Alcaraz-estrada SL, Mondragón-terán P, Suárez-cuenca JA, Coral-vázquez RM, Garcia S. Neurological Involvement in Pediatric Patients with Acute Leukemia: A Retrospective Cohort. Children 2022;9:1268. [DOI: 10.3390/children9091268] [Reference Citation Analysis]
158 Sun M, Cyr M, Sandoval J, Perreault LL, Busque L, Tardif J, Dubé M. Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors: an analysis of the UK Biobank.. [DOI: 10.1101/2022.08.20.22279019] [Reference Citation Analysis]
159 Ungerstedt J, Ljung C, Klimkowska M, Gülen T. Clinical Outcomes of Adults with Systemic Mastocytosis: A 15-Year Multidisciplinary Experience. Cancers 2022;14:3942. [DOI: 10.3390/cancers14163942] [Reference Citation Analysis]
160 Xie Z, Zeidan AM. CHIPing away the progression potential of CHIP: A new reality in the making. Blood Rev 2022;:101001. [PMID: 35989137 DOI: 10.1016/j.blre.2022.101001] [Reference Citation Analysis]
161 Crupi F, Sordi B, Vanderwert F, Gesullo F, Amorosi A, Mannelli F, Santi R. Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management. Int J Mol Sci 2022;23:8772. [PMID: 35955907 DOI: 10.3390/ijms23158772] [Reference Citation Analysis]
162 Ghandili S, Modemann F, Oelrich J, Bokemeyer C, Fiedler W. Aktueller diagnostischer Standard und Risikostratifizierung der AML. InFo Hämatol Onkol 2022;25:10-15. [DOI: 10.1007/s15004-022-9124-1] [Reference Citation Analysis]
163 Waksal JA, Tremblay DA. Contemporary and future strategies in polycythemia vera. Best Practice & Research Clinical Haematology 2022. [DOI: 10.1016/j.beha.2022.101370] [Reference Citation Analysis]
164 Rampotas A, Hargreaves R, Mclornan DP. Challenges of diagnosing and managing pre-fibrotic myelofibrosis: A case-based and practical approach. Best Practice & Research Clinical Haematology 2022. [DOI: 10.1016/j.beha.2022.101378] [Reference Citation Analysis]
165 Zhang TJ, Xu ZJ, Wen XM, Gu Y, Ma JC, Yuan Q, Lin J, Zhou JD, Qian J. SLIT2 promoter hypermethylation-mediated SLIT2-IT1/miR-218 repression drives leukemogenesis and predicts adverse prognosis in myelodysplastic neoplasm. Leukemia 2022. [PMID: 35906386 DOI: 10.1038/s41375-022-01659-1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
166 Gaulin C, Kelemen K, Arana Yi C. Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm. Life (Basel) 2022;12:1135. [PMID: 36013314 DOI: 10.3390/life12081135] [Reference Citation Analysis]
167 Girard S, Genevieve F, Rault E, Fenneteau O, Lesesve J. When Ring Sideroblasts on Bone Marrow Smears Are Inconsistent with the Diagnosis of Myelodysplastic Neoplasms. Diagnostics 2022;12:1752. [DOI: 10.3390/diagnostics12071752] [Reference Citation Analysis]
168 El Hussein S, Chifotides HT, Khoury JD, Verstovsek S, Thakral B. Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update. Cancers (Basel) 2022;14:3474. [PMID: 35884535 DOI: 10.3390/cancers14143474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Hoermann G. Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease. Diagnostics 2022;12:1613. [DOI: 10.3390/diagnostics12071613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]